Individuals with obesity are more likely to have a benign blood condition that often precedes multiple myeloma, according to new research to be published in Blood Advances. People who are physically active, meanwhile, are less likely to have this condition, even if they are obese. Smoking and too little sleep…

Biological sex and gender have a large impact on the presentation of a disease, its progression, and how it is treated, but these factors have not received adequate research or clinical attention. Positive signs of change are emerging, but there is a lot that needs to be achieved before these…

Oriana Papin-ZoghbiCEO and co-founder, AOA Dx Women have been severely underserved when it comes to their health,” says Oriana Papin-Zoghbi, CEO and co-founder of AOA Dx, which is based in Boulder, CO. Bold as that statement sounds, many experts and organizations around the world point out…

Two new deals around antibody drug conjugates (ADCs) were just struck. Pfizer will develop and commercialize Nona Biosciences’ MSLN-targeted ADC HBM9033 in a deal worth potentially $1B+. Meanwhile, Biocytogen Pharmaceuticals announced an antibody evaluation, option, and license agreement with Ona Therapeutics. The deal includes an option to exclusively license selected…

Gene editing company Cellectis stands to collect as much as $245 million in cash and equity investment in the company via a collaboration with AstraZeneca as the pharma giant continues its push into the cell and gene therapy space. Under the terms of the agreement AstraZeneca will gain access to…

Research led by Shanghai Jiao Tong University School of Medicine and the Chan School of Public Health in Boston suggests that there may be more long-term health risks associated with gestational diabetes than previously thought even in women who do not go on to develop type 2 diabetes. Using data…

In 2012, 6-year-old Emily Whitehead’s acute lymphoblastic leukemia returned, and no traditional treatment options remained. So she became the first child to receive CAR-T immunotherapy, which engineered her T cells to fight the cancer. More than a decade later, Emily is cancer-free. Her success spawned new hope that immunotherapy could…

In the latest high profile antibody drug conjugate (ADC) deal, this week Hangzhou-based Bliss Biopharmaceutical (BlissBio) announced a clinical trial collaboration agreement with Eisai for its lead ADC BB-1701, which is in Phase I/II in China and the U.S. BB-1701 has an eribulin-payload directed against Human Epidermal Growth Factor Receptor…

More than 20 years ago, the announcement of the completion of the first human genome was heralded, often breathlessly, as the dawn of a new age of medicine. But how far have we actually come in using an individual’s unique molecular make up to provide individually tailored care based on…

William Haseltine With every possible combination of salt, fat, and sugar lining our grocery stores and filling fast-food restaurants, the temptation to eat junk food often feels too hard to resist. These foods tap into our deep carnal desire for pleasure. Think about the last time…

When people think of health inequity, it is often in terms of racial disparities—Black men being two times more likely to die from prostate cancer, for instance. The causes of these inequities comprise a range of factors, from the biological to the social, environmental, and economic. In short, good health…

Gilead Sciences and EVOQ Therapeutics have announced a collaboration around EVOQ’s proprietary NanoDisc technology for the treatment of rheumatoid arthritis (RA) and lupus. NanoDisc is designed to enable lymph targeted delivery of disease-specific antigens for autoimmune diseases. The two companies will collaborate on preclinical development. EVOQ could receive up to…

Repare Therapeutics has inked a worldwide agreement with Roche for the development and commercialization of camonsertib (RP-3500), an oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related protein kinase) currently in phase I/II trials. The drug was created using Repare’s proprietary synthetic lethality platform and targets tumors with specific genomic…

Digital biology drug discovery company Recursion has secured a commitment of up to $12 billion from Roche and its Genetech subsidiary to apply its Recursion Operating Systemt (OS) to advance therapies across 40 program that include neuroscience and an undisclosed oncology indication the companies announced today. Recursion OS applies machine…

Research from a mouse study carried out by the University of Kentucky suggests that having an unhealthy or disrupted gut microbiome could impair muscle growth. The gut microbiome is known to impact many different areas in our bodies and have a big influence our overall health. There have been a…